News

Understanding Recent Stock Sales by Rep. Thomas Kean: Insights

Understanding Recent Stock Sales by Rep. Thomas Kean: Insights

Overview of Stock Transactions by Rep. Thomas Kean

Recently, Representative Thomas Kean disclosed a transaction involving Johnson & Johnson (NYSE: JNJ) stock, reporting a sale valued between $30,002 and $100,000. The report indicates that this transaction occurred on November 20, 2025, with the disclosure published shortly after in December.

As of now, shares of Johnson & Johnson are trading at $206.89, reflecting a 0.25% increase. This uptick may be small, but it highlights the ongoing fluctuations in the stock market that stakeholders pay close attention to.

Past Trading Activities by Representative Kean

In recent years, Thomas Kean's trading activities have been quite notable. He has engaged in a total of 120 stock transactions, accumulating over $597,000 in trade value, which includes significant dealings in his portfolio with noteworthy stocks such as Aon and Johnson & Johnson.

A Closer Look at Recent Transactions

Here are some highlights of Thomas Kean's notable trades in the past:

  • Fiserv (NASDAQ: FISV): Sale valued between $1,001 and $15,000
  • Intercontinental Exchange (NYSE: ICE): Purchase valued between $1,001 and $15,000

Importance of Congressional Stock Transactions

Understanding congressional transactions offers insights into the financial decisions of elected officials. A congressional transaction refers to any purchase or sale of stocks by a member of Congress.

Members of Congress are required to submit a Periodic Transaction Report within 30 days of completing a transaction, as mandated by law. This requirement enhances transparency and ensures that elected representatives are accountable to the public regarding their financial activities.

Legislation Affecting Stock Trading by Congress Members

The STOCK Act plays a crucial role in the regulation of stock trading by Congress members. Enacted in April 2012, this law prohibits the use of non-public information for personal gain in stock trading.

Investment Implications of Congressional Transactions

While congressional transactions should not exclusively dictate investment decisions, they can still influence investor perspectives. When a representative makes purchase decisions, it may signal an expectation of rising stock values, possibly offering cues for potential buyers.

Conversely, sales may arise from various motivations, which do not necessarily imply a negative outlook on a stock's future performance. Evaluating these trends can be beneficial for investors looking to make informed choices.

Frequently Asked Questions

What was the value of Rep. Thomas Kean's stock sale?

The value of Representative Thomas Kean's stock sale of Johnson & Johnson was reported to be between $30,002 and $100,000.

What are the key stocks in Thomas Kean's portfolio?

Thomas Kean's portfolio includes significant holdings in companies like Aon and Johnson & Johnson, along with multiple transactions involving other large stocks.

What does the STOCK Act prohibit?

The STOCK Act prohibits members of Congress from using non-public information acquired through their position for personal financial gain.

How often must Congress members report their stock trades?

Congress members must report their stock trades within 30 days of the transaction and within 45 days of being notified.

Why should investors pay attention to congressional transactions?

Investors may find congressional transactions insightful as they can reflect potential market trends and indicate how elected officials view certain stocks.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 9

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 11

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 19

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading

Top 5 Most Recently Viewed Articles

America's Car-Mart Secures $300 Million Loan for Growth

Updated Category News Views 255

America's Car-Mart Secures Funding for Future Growth America's Car-Mart, Inc. (NASDAQ: CRMT), a leading automotive retailer, has taken a strategic step by closing a significant five-year, $300 million term loan. This loan, managed by the seasoned professionals at Silver Point Capital, L.P., aims to enhance the company’s capital structure and support its long-term growth...

Continue Reading
IASO Bio's Breakthrough Drug Application Acceptance in Singapore

Updated Category News Views 251

IASO Bio’s Major Step Forward with New Drug Application IASO Biotherapeutics, a pioneering biopharmaceutical company dedicated to the advancement of innovative cell therapies and biologics, has reached a significant milestone. The Singapore Health Sciences Authority (HSA) has officially accepted the New Drug Application (NDA) for Equecabtagene Autoleucel, known as...

Continue Reading
Creating Community Leaders: National Heritage Academies and United Way

Updated Category News Views 150

Empowering Students to Make a Difference The student-led organization is providing career opportunities while connecting with the community. National Heritage Academies® (NHA) is thrilled to celebrate its collaboration with United Way through the Student United Way program. This initiative equips high school students with essential tools and opportunities to enact...

Continue Reading
Future Growth of Augmented and Virtual Reality Technologies

Updated Category News Views 259

Exploring the Growth of Augmented Reality and Virtual Reality Market The global market for Augmented Reality (AR) and Virtual Reality (VR) is on the rise, with expectations of substantial growth over the next few years. Analysts estimate that this sector will expand by approximately USD 442.99 billion between 2024 and 2028. The compound annual growth rate (CAGR) for this...

Continue Reading
ImmVira Launches Innovative Exosome, Transforming Cosmetics

Updated Category News Views 407

ImmVira Leads the Way with Groundbreaking Exosome Technology In a remarkable advancement for the cosmetic industry, ImmVira Group has announced its innovative product, MVR-EX103, an engineered exosome specifically developed for treating superficial skin depressions. This development marks a pivotal moment, as it has successfully acquired the International Nomenclature...

Continue Reading